Last reviewed · How we verify
Ticagrelor standard tablets
Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.
Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events. Used for Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), Secondary prevention of atherothrombotic events in patients with a history of myocardial infarction.
At a glance
| Generic name | Ticagrelor standard tablets |
|---|---|
| Sponsor | Azienda Ospedaliero Universitaria di Sassari |
| Drug class | P2Y12 receptor antagonist (antiplatelet agent) |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelet surfaces, blocking platelet activation and aggregation. This antiplatelet effect reduces the formation of pathological blood clots in coronary arteries and other vascular beds. Unlike clopidogrel, ticagrelor's reversible binding allows faster platelet function recovery upon drug discontinuation.
Approved indications
- Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)
- Secondary prevention of atherothrombotic events in patients with a history of myocardial infarction
Common side effects
- Bradycardia
- Dyspnea
- Bleeding (major and minor)
- Ventricular pauses
- Hyperuricemia
Key clinical trials
- Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy (PHASE4)
- Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies (PHASE4)
- Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI (PHASE4)
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
- Ticagrelor Administered as Standard Tablet or Orodispersible Formulation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor standard tablets CI brief — competitive landscape report
- Ticagrelor standard tablets updates RSS · CI watch RSS
- Azienda Ospedaliero Universitaria di Sassari portfolio CI